Compounds > 2-amino-4-methylbenzothiazole
Page last updated: 2024-12-05

2-amino-4-methylbenzothiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-amino-4-methylbenzothiazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15132
CHEMBL ID1343355
SCHEMBL ID94937
MeSH IDM0574013

Synonyms (64)

Synonym
BIDD:GT0043
4-methyl-benzothiazol-2-ylamine
BB 0246262
4-methyl-2-aminobenzothiazole
nsc-28732
nsc28732
4-methyl-2-benzothiazolamine
4-methyl-2-aminobenzothiozole
2-benzothiazolamine, 4-methyl-
1477-42-5
wln: t56 bn dsj cz h1
2-amino-4-methylbenzothiazole
benzothiazole, 2-amino-4-methyl-
NCGC00091579-01
4-methylbenzothiazol-2-ylamine
brn 0129346
einecs 216-028-3
nsc 28732
4-methyl-1,3-benzothiazol-2-amine
4-methylbenzothiazole-2-ylamine
2-amino-4-methylbenzothiazole, 97%
inchi=1/c8h8n2s/c1-5-3-2-4-6-7(5)10-8(9)11-6/h2-4h,1h3,(h2,9,10
STK400194
AC-6243
AKOS000111778
HMS1655B11
4-methylbenzo[d]thiazol-2-amine
A23682
NCGC00091579-02
2-amino-4-methyl benzothiazole
unii-45v5f1b9z8
4-27-00-04905 (beilstein handbook reference)
45v5f1b9z8 ,
NCGC00257787-01
dtxsid9024487 ,
tox21_200233
dtxcid404487
cas-1477-42-5
F1911-0001
AM803235
AS-871/40209246
4-methyl-1,3-benzothiazol-2-ylamine
FT-0611126
CHEMBL1343355
benzothiazole, 1-amino-3-methyl-
2-amino-4-methylbenzo(d)thiazole
4-methylbenzo(d)thiazol-2-amine
amino-4-methylbenzothiazole, 2-
SCHEMBL94937
2-amino-methylbenzothiazole
4-methyl-2-amino-1,3-benzothiazole
4-methyl-2-amino benzothiazole
4-methly-2-amino benzothiazole
mfcd00005793
SY020320
4-methyl-1,3-benzothiazol-2-amine #
W-108112
BBL036206
Z56174289
CS-W014311
AS-10773
Q27258873
4-chloro-1-methyl-3-(2-methylpropyl)-1h-pyrazole-5-carboxylicacidethylester
EN300-16557
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency80.68140.007215.758889.3584AID1224835
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency49.93960.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency65.65240.003041.611522,387.1992AID1159553; AID1159555
pregnane X nuclear receptorHomo sapiens (human)Potency55.14820.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.52130.000229.305416,493.5996AID588514; AID743075
aryl hydrocarbon receptorHomo sapiens (human)Potency39.55660.000723.06741,258.9301AID651777; AID743085; AID743122
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency25.11890.010039.53711,122.0200AID588547
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency11.37500.000627.21521,122.0200AID651741; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1059430Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-hydroxybenzaldehyde
[no description available]		2.0810hydroxybenzaldehydeEC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor;
mouse metabolite;
plant metabolite
catechol
[no description available]		2.0810catecholsallelochemical;
genotoxin;
plant metabolite
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		2.0810monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
benzoxazolone
benzoxazolone: RN given refers to parent cpd; structure. 2-benzoxazolinone : A member of the class of benzoxazoles that is 2,3-dihydro-1,3-benzoxazole carrying an oxo group at position 2.		2.0810benzoxazoleallelochemical;
phytoalexin
4-nitrobenzoic acid
4-nitrobenzoic acid: RN given refers to parent cpd. 4-nitrobenzoic acid : A nitrobenzoic acid having the nitro group at the 4-position.		2.0810nitrobenzoic acid
3-methylsalicylic acid
3-methylsalicylic acid : A monohydroxybenzoic acid consisting of salicylic acid carrying a methyl group at the 3-position.		2.0810monohydroxybenzoic acidbacterial xenobiotic metabolite
1,5-dihydroxynaphthalene
[no description available]		2.0810
5-methylsalicylic acid
[no description available]		2.0810
4,4'-dihydroxybiphenyl
biphenyl-4,4'-diol : A member of the class of hydroxybiphenyls that is biphenyl with hydroxy groups at positions 4 and 4'.		2.0810hydroxybiphenyls
benzothiazole
benzothiazole: structure. benzothiazole : An organic heterobicyclic compound that is a fusion product between benzene and thiazole. The parent of the class of benzothiazoles.		2.0810benzothiazolesenvironmental contaminant;
plant metabolite;
xenobiotic
phenylhydrazine
[no description available]		2.0810phenylhydrazinesxenobiotic
dibenzothiazyl disulfide
dibenzothiazyl disulfide: vulcanizing accelerant. dibenzothiazol-2-yl disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of two molecules of 1,3-benzothiazole-2-thiol. It is used as an accelerator in the rubber industry.		2.0810benzothiazoles;
organic disulfide		allergen
2-aminobenzothiazole
[no description available]		2.0810benzothiazoles
thiazoles
[no description available]		2.07101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
4-methylcatechol
[no description available]		2.0810methylcatecholantioxidant;
carcinogenic agent;
hapten;
human metabolite;
plant metabolite
ninhydrin
Ninhydrin: 2,2-Dihydroxy-1H-indene-1,3-(2H)-dione. Reagent toxic to skin and mucus membranes. It is used in chemical assay for peptide bonds, i.e., protein determinations and has radiosensitizing properties.. ninhydrin : A member of the class of indanones that is indane-1,3-dione bearing two additional hydroxy substituents at position 2.		2.0810aromatic ketone;
beta-diketone;
indanones;
ketone hydrate		colour indicator;
human metabolite
hydroxyhydroquinone
benzene-1,2,4-triol : A benzenetriol carrying hydroxy groups at positions 1, 2 and 4.		2.0810benzenetriolmouse metabolite
6-hydroxyquinoline
quinolin-6-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 6.		2.0810monohydroxyquinoline
2,7-dihydroxynaphthalene
[no description available]		2.0810
pentafluorobenzoic acid
[no description available]		2.0810perfluorinated compound
1,3-indandione
1,3-indandione : A member of the class of indanones that is indane in which the hydrogens at positions 2 and 4 have been replaced by oxo groups.		2.0810aromatic ketone;
beta-diketone;
indanones
5-methylbenzimidazole
5-methylbenzimidazole: structure in first source. 5-methyl-1H-benzimidazole : A member of the class of imidazoles that is 1H-benzimidazole in which the hydrogen at position 5 is substituted by a methyl group.		2.0810imidazoles
2-hydrazinobenzothiazole
[no description available]		2.0810
3-acetylindole
3-acetylindole: structure in first source		2.0810
2-hydroxybenzothiazole
2-hydroxybenzothiazole : Benzothiazole substituted with a hydroxy group at the 2-position.		2.0810benzothiazole
phenylhydroquinone
phenylhydroquinone: major metabolite of o-phenylphenol; cleaves DNA; structure given in first source		2.0810
2,2'-biphenol
biphenyl-2,2'-diol : A member of the class of hydroxybiphenyls carrying hydroxy groups at positions 2 and 2'.		2.0810hydroxybiphenyls
salicylhydroxamic acid
[no description available]		2.0810hydroxamic acid;
phenols		antibacterial drug;
EC 1.11.2.2 (myeloperoxidase) inhibitor;
EC 3.5.1.5 (urease) inhibitor;
trypanocidal drug
5-fluorosalicylic acid
5-fluorosalicylic acid: structure given in first source; product from action of alkaline phosphatase on 5-fluorosalicyl phosphate; forms highly fluorescent terbium ternary complex		2.0810
1,8-diaminonaphthalene
1,8-diaminonaphthalene: structure in first source		2.0810
4(5)-phenylimidazole
4(5)-phenylimidazole: tautomeric cpd; cytochrome P450 14alpha-sterol demethylase, CYP51 antagonist		2.0810
biphenyl-2-carboxylic acid
biphenyl-2-carboxylic acid: structure in first source		2.0810
4-Methoxybenzamide
[no description available]		2.0810benzamides
2-(carboxymethylthio)benzothiazole
2-(carboxymethylthio)benzothiazole: oxidation product of 2-(hydroxyethylthio)benzothiazole; structure given in first source		2.0810
2,6-dihydroxynaphthalene
[no description available]		2.0810naphthols
captax
captax: RN given refers to parent cpd. 1,3-benzothiazole-2-thiol : 1,3-Benzothiazole substituted at the 2-position with a sulfanyl group.		2.0810aryl thiol;
benzothiazoles		carcinogenic agent;
metabolite
4-nitrocatechol
4-nitrocatechol : A member of the class of catechols that is benzene-1,2-diol substituted by a nitro group at position 4.It is the by-product of the hydroxylation of p-nitrophenol.		2.0810C-nitro compound;
catechols		human xenobiotic metabolite;
lipoxygenase inhibitor
esculetin
esculetin: used in filters for absorption of ultraviolet light; structure. esculetin : A hydroxycoumarin that is umbelliferone in which the hydrogen at position 6 is substituted by a hydroxy group. It is used in filters for absorption of ultraviolet light.		2.0810hydroxycoumarinantioxidant;
plant metabolite;
ultraviolet filter
7-hydroxycoumarin-4-acetic acid
7-hydroxycoumarin-4-acetic acid: pH-indicator dye; structure in first source		2.0810
dufulin
dufulin: structure in first source		2.110
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310